Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
The company plans to add 1700 beds by FY27 through the organic route
International Business is expected to register double-digit growth in constant currency terms
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
New leadership team announced at NATHEALTH Annual General Meeting 2024
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Subscribe To Our Newsletter & Stay Updated